

Oidov Baatarkhuu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2763237/publications.pdf>

Version: 2024-02-01

37
papers

2,902
citations

393982

19
h-index

395343

33
g-index

41
all docs

41
docs citations

41
times ranked

4356
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	3.7	1,619
2	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	3.7	237
3	Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatology International, 2020, 14, 690-700.	1.9	210
4	The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2. Journal of Viral Hepatitis, 2015, 22, 26-45.	1.0	117
5	Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2. Journal of Viral Hepatitis, 2015, 22, 6-25.	1.0	92
6	APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatology International, 2021, 15, 1031-1048.	1.9	56
7	Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma. Journal of Medical Virology, 2009, 81, 1002-1008.	2.5	50
8	Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2. Journal of Viral Hepatitis, 2015, 22, 46-73.	1.0	47
9	The global case fatality rate of coronavirus disease 2019 by continents and national income: A meta-analysis. Journal of Medical Virology, 2022, 94, 2402-2413.	2.5	46
10	Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia. Journal of Medical Virology, 2006, 78, 542-550.	2.5	43
11	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. Digestive Diseases and Sciences, 2015, 60, 573-581.	1.1	34
12	Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study. Liver International, 2008, 28, 1389-1395.	1.9	33
13	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2016, 14, 1647-1656.e6.	2.4	32
14	Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 57-62.	0.1	26
15	Current Situation of Hepatocellular Carcinoma in Mongolia. Oncology, 2011, 81, 148-151.	0.9	25
16	Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. Journal of Viral Hepatitis, 2017, 24, 141-147.	1.0	23
17	Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study. Hepatology International, 2012, 6, 763-769.	1.9	22
18	Viral Hepatitis and Liver Diseases in Mongolia. Euroasian Journal of Hepato-gastroenterology, 2017, 7, 68-72.	0.1	21

#	ARTICLE	IF	CITATIONS
19	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019, 9, 2508.	1.6	20
20	Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients. <i>Journal of Medical Virology</i> , 2009, 81, 594-601.	2.5	19
21	Variability in liver stiffness values from different intercostal spaces. <i>Liver International</i> , 2009, 29, 760-766.	1.9	19
22	Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2808-2810.e2.	2.4	17
23	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00036.	1.3	17
24	Seroprevalence survey of brucellosis among rural people in Mongolia. <i>Western Pacific Surveillance and Response Journal: WPSAR</i> , 2014, 5, 13-20.	0.3	14
25	Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1528-1534.	1.4	13
26	Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000119.	1.1	10
27	Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 147-153.	4.5	9
28	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3660-3668.	1.1	8
29	Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database. <i>Cancer Research and Treatment</i> , 2019, 51, 1347-1356.	1.3	8
30	Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. <i>Liver International</i> , 2019, 39, 81-89.	1.9	4
31	Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 712-719.	0.8	3
32	Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 125-135.	4.5	3
33	The Role of Human Genetic Factors in the Natural Selection of Hepatitis C Virus™ Dominant Genotype in Ethnically Close Populations of Buryats and Khalkha-Mongols. <i>Sovremennye Tehnologii V Medicine</i> , 2018, 10, 21.	0.4	3
34	Clinical features and outcome of acute hepatitis B and Delta in Mongolia: one-year follow-up study. <i>Infectious Diseases: News, Opinions, Training</i> , 2021, 10, 8-14.	0.1	0
35	PECULIARITIES OF THE III TYPE INTERFERON GENES™ POLYMORPHISM IN HCV PATIENTS ON THE CROSS-BORDER REGIONS OF RUSSIA AND MONGOLIA. <i>Jurnal Infektologii</i> , 2017, 9, 46-53.	0.1	0
36	CLINICAL AND EPIDEMIOLOGICAL MANIFESTATION OF HEPATOCELLULAR CARCINOMA IN PATIENTS BELONGING TO ETHNIC GROUPS OF CAUCASIANS AND ASIANS OF NORTH-EAST ASIA. <i>Zhurnal Mikrobiologii i Immunologii</i> , 2018, , 25-31.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Hepatocellular carcinoma associated with hepatitis B and C in mongoloids and caucasians of North-East Asia. Infectious Diseases: News, Opinions, Training, 2021, 10, 38-44.	0.1	0